ProMIS Neurosciences Inc.

Expert Comments:

Biotech's Data Well Received at Neurodegenerative Diseases Symposium (6/28/19) The company shared findings from its lead clinical program, in Alzheimer's disease. read more >
Biotech in Neuro Diseases Adds Parkinson's Expert to Scientific Advisory Board (6/22/19) The expert brings to the board a deep knowledge of neurodegeneration. read more >
Biotech to Present Alzheimer's Disease Therapeutic at Keystone Symposium (6/8/19) The focus will be the Canadian company's lead monoclonal antibody candidate. read more >
Biotech Identifies Antibodies for Toxic Tau in Alzheimer's Disease (5/28/19) The Canadian company's approach to this indication is now twofold. read more >
Cosme Ordonez, Noble Capital Markets (5/15/19) "The progress made in ProMIS Neurosciences Inc.'s Parkinson's program was presented at the 14th International Conference on Alzheimer's and Parkinson's Diseases held in Lisbon, Portugal, from March 26 to 31, 2019. The company was able to showcase results demonstrating the selectivity of anti-alpha synuclein antibodies, which selectively bind to toxic forms of alpha synuclein while sparing the normal form of this protein present in healthy cells."
Clive Maund, CliveMaund.com (5/12/19) "ProMIS Neurosciences Inc. has done as expected and is a Buy again here. . .it is now showing signs that it is ready to advance anew, at a time when the broad market is showing signs that it is ready to bounce back after its trade deal shock."
Biotech Stresses Need to Target Only Toxic Oligomer in Alzheimer's Therapies (3/25/19) The company cites the recent discontinuation of other firms' clinical programs as proof. read more >
Cosme Ordonez, Noble Capital Markets (3/21/19) "ProMIS Neurosciences Inc. is developing a novel therapeutic approach targeting a completely different molecular target [from Biogen's]. . .in light of Biogen's failure, we believe that ProMIS will emerge as a leader in the Alzheimer's area with a potentially disease modifying therapy. . .the currently deflated share price does not reflect the potential of ProMIS' lead drug and product pipeline."
	André Uddin, Mackie Research Capital (3/21/19) "ProMIS Neurosciences Inc. has identified multiple targets for neurodegenerative disorders: an alpha synuclein for Parkinson's, tau for Alzheimer's and SOD1 and TDP43 for amyotrophic lateral sclerosis; we expect the company to outlicense these targets and related candidates. A licensing deal could be forged in Q2/19 or Q3/19 for one of these drug candidates; multiple players are currently at the table."
Antibody Therapeutics Developer to Present at March Alzheimer's/Parkinson's Conference (3/19/19) The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein. read more >
André Uddin, Mackie Research Capital (3/15/19) "ProMIS Neurosciences Inc. is to initiate a Phase 1 study with PMN310 in both healthy subjects and prodromal/mild Alzheimer's patients (total n=8) in H2/19; results of this trial are expected in late 2020. Results of Biogen's Phase 3 ENGAGE trial with aducanumab are also expected in 2020; positive ENGAGE results could potentially enable ProMIS to piggyback on that data, enabling it to potentially outlicense PMN310."
Clive Maund, CliveMaund.com (3/10/19) "ProMIS Neurosciences Inc. is a biotech stock that is working out well for us. . .the long-term outlook for the company and its stock is excellent."
Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease (2/13/19) The Canadian company continues seeking partners to leverage its discovery and development platform. read more >
Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments (2/2/19) This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings. read more >

More Expert Comments

	André Uddin, Mackie Research Capital (2/27/19) "Through its platform, ProMIS Neurosciences Inc. has identified multiple targets for various central nervous system disorders: SOD1 for amyotrophic lateral sclerosis (ALS), TDP43 for ALS, alpha-synuclein for Parkinson's and tau for Alzheimer's. . .we expect the company to out-license those targets/candidates. . .we expect a licensing deal to be forged in Q2/19 or Q3/19; multiple players are currently at the table."
Cosme Ordonez, Noble Capital Markets (2/15/19) "We are initiating coverage on ProMIS Neurosciences Inc. with an Outperform rating and a $1 target price. . .we believe the company's stock is undervalued and does not reflect the significant potential of its lead drug PMN310. The signing of a high value partnership could act as a key catalyst for the stock."
	André Uddin, Mackie Research Capital (11/13/18) "ProMIS Neurosciences Inc. is looking to initiate a Phase 1 study with PMN310 in both healthy subjects and prodromal/mild Alzheimer's patients (a total of eight subjects) in H2/19. . .the company is looking to outlicense PMN310 after the Phase 1 study. . .it is looking to outlicense its anti-H-synuclein assets for Parkinson's disease."
John Vandermosten, Zacks Small-Cap Research (8/22/18) "ProMIS Neurosciences Inc. anticipates launching its first in-human trial in 2019 following additional validation of lead candidate, PMN310. . .while still in early stage development, PMN310 makes a compelling case for success and should hold a dominant position in the market if trials are successful and regulatory approval is granted." -Zacks Small-Cap Research
	André Uddin, Mackie Research Capital (8/14/18) "ProMIS Neurosciences Inc. recently identified various mAb candidates against two new targets for neurodegenerative diseases: alpha-synuclein for Parkinson's disease and TDP43 for amyotrophic lateral sclerosis. The company is looking to forge partnerships for these assets; we are not assuming any related deal in our model at this time."
John Vandermosten, Zacks Small-Cap Research (6/27/18) "We are initiating coverage of ProMIS Neurosciences Inc. with a $7 price target based on our forecast for product sales after a 2027 launch of its lead candidate PMN310 in the United States, European Union and rest of world. . .the company's lead candidate is currently in preclinical development and is expected to begin Phase 1 trials in 2019." -Zacks Small-Cap Research
	André Uddin, Mackie Research Capital (3/14/18) "We are maintaining our Speculative Buy rating and our target price of $0.70 on ProMIS Neurosciences Inc. . .the company plans to initiate a single ascending dose, Phase 1 trial with PMN310 in 2019. It is also seeking to forge partnerships with big pharmas for other pipeline candidates."
André Uddin, Mackie Research Capital (1/23/18) "ProMIS Neurosciences Inc. reported that its PMN310 demonstrated significantly greater binding to toxic amyloid beta oligomers than Biogen's aducanumab in preclinical studies, a positive signal for better efficacy. . .we believe a licensing deal could come in as early as 2018. . .we are maintaining our Speculative Buy rating and increasing our target price to CA$0.70 from CA$0.50 previously."
André Uddin, Mackie Research Capital (1/4/18) "ProMIS Neurosciences Inc. reported that PMN310 demonstrated no amyloid beta plaque binding in preclinical studies, a positive signal for improved safety. . .in terms of preclinical safety, PMN310 appears to be better than Biogen's aducanumab, which should facilitate a potential licensing deal for PMN310. We believe a licensing deal could come in as early as 2018."
André Uddin, Mackie Research Capital (11/13/17) "ProMIS Neurosciences Inc.'s fully diluted Q3/17 EPS of $0.01 compared to $0 last year. . .as of Q3/17E, the company had $3.3M in cash and zero debt on its balance sheet. . .we are maintaining our Speculative Buy rating and target price of CA$0.50/share."
André Uddin, Mackie Research Capital (10/17/17) "ProMIS Neurosciences Inc. announced that its lead Alzheimer's monoclonal antibody (mAb) candidate, PMN310, showed a high degree of selectivity to target amyloid beta oligomers when compared to other amyloid beta-directed mAbs in a preclinical study. . .given the favorable preclinical results, we remain confident that PMN310 should have better efficacy and safety than Biogen's aducanumab and [that] PMN310 has best-in-class potential to treat Alzheimer's."
André Uddin, Mackie Research Capital (9/19/17) "We are initiating coverage of Promis Neurosciences Inc. . .a promising new path for targeting Alzheimer's (AD). A therapy to treat the underlying cause of Alzheimer's disease represents an enormous market opportunity. . .Promis' lead mAb (monoclonal antibody) drug candidate, PMN310, was rationally designed to target toxic amyloid beta (AB) oligomers. AB is a “sticky” peptide (monomer) which clumps together to form toxic oligomers, which can in turn form plaque deposits. . .this newer theory is strongly backed by the Phase 1b success of Biogen's aducanumab which targets toxic AB oligomers. . .we believe this newer AD theory creates a path to develop a unique disease-modifying Alzheimer's treatment, PMN310 which has best-in-class potential."
	Douglas Loe, Echelon Wealth Partners (9/13/17) "ProMIS Neurosciences Inc. announced that a third therapy has been identified for the firm's Alzheimer's disease pipeline. The asset in question is PMN330, a mAb targeting amyloid-beta oligomers, and we assume the mAb is one of many based on CSO Neil Cashman's expertise in developing mAbs that target misfolded protein antigens. . .the asset will join two other identified lead compounds PMN310 and PMN350, with PMN310 still set to be the first lead asset to enter formal clinical trials by 2019."

Experts Following This Company

Clive Maund – CliveMaund.com
	André Uddin – Mackie Research Capital
John Vandermosten, CFA – Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.